B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Genomic Characterization of de novo Metastatic Breast Cancer
Ana C. Garrido-Castro,Liam F. Spurr,Liam F. Spurr,Melissa E. Hughes,Yvonne Y. Li,Yvonne Y. Li,Andrew D. Cherniack,Andrew D. Cherniack,Priti Kumari,Maxwell R. Lloyd,Brittany L. Bychkovsky,Romualdo Barroso-Sousa,Simona Di Lascio,Esha Jain,Esha Jain,Janet Files,Ayesha Mohammed-Abreu,Max Krevalin,Colin Mackichan,William T. Barry,Hao Guo,Daniel Xia,Daniel Xia,Ethan Cerami,Barrett J. Rollins,Barrett J. Rollins,Laura E. MacConaill,Laura E. MacConaill,Neal I. Lindeman,Neal I. Lindeman,Ian E. Krop,Bruce E. Johnson,Nikhil Wagle,Nikhil Wagle,Eric P. Winer,Deborah A. Dillon,Deborah A. Dillon,Nan Lin +37 more
TL;DR: Genomic differences between treatment-naïve dnMBC and primary tumors of patients who developed rMBC may provide insight into mechanisms underlying metastatic potential and differential therapeutic sensitivity in dn MBC.
Journal ArticleDOI
ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study
John V. Heymach,R.-P. Dong,I. Dimery,C. Wheeler,Panos Fidias,Charles Lu,Bruce E. Johnson,Roy S. Herbst +7 more
TL;DR: This phase has confirmed that the combination of ZD6474 and doc is not associated with significant changes in exposure to either drug and the toxicities are manageable, and preliminary PK assessment shows that ZD 6474 did not appear to affect exposure to doc, with any changes observed being similar to the intra-patient variability for doc alone.
Journal ArticleDOI
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
Xinan Wang,Biagio Ricciuti,Joao Victor Machado Alessi,Tom C. Nguyen,Mark M. Awad,Xihong Lin,Bruce E. Johnson,David C. Christiani +7 more
TL;DR: In this article, a study was conducted on 644 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy between April 2013 and September 2020 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos,Scott L. Carter,Sandro Santagata,Daniel P. Cahill,Amaro Taylor-Weiner,Robert T. Jones,E.M. Van Allen,Michael S. Lawrence,Peleg M. Horowitz,Kristian Cibulskis,Keith L. Ligon,Josep Tabernero,Joan Seoane,Elena Martínez-Sáez,William T. Curry,Ian F. Dunn,Sun Ha Paek,Sung Hye Park,Aaron McKenna,Aaron Chevalier,Mara Rosenberg,Fred G. Barker,Corey M. Gill,P. Van Hummelen,Aaron R. Thorner,Bruce E. Johnson,Mai P. Hoang,Toni K. Choueiri,Sabina Signoretti,Carrie Sougnez,Michael S. Rabin,Nan Lin,Eric P. Winer,Anat Stemmer-Rachamimov,Matthew Meyerson,Levi A. Garraway,S. Gabriel,Eric S. Lander,Rameen Beroukhim,Tracy T. Batchelor,J. Baselga,David N. Louis,Gad Getz,William C. Hahn +43 more
TL;DR: Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy.
Journal ArticleDOI
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Panos Fidias,Nathan A. Pennell,Anthony L. Boral,Geoffrey I. Shapiro,Arthur T. Skarin,Joseph Paul Eder,T Jesse Kwoh,Richard S. Geary,Bruce E. Johnson,Thomas J. Lynch,Jeffrey G. Supko +10 more
TL;DR: Combining cytotoxic chemotherapeutic agents with inhibitors of aberrant signal transduction mediated by Raf proteins produced no objective responses in the dose and schedule administered in this study.